Events
ASCO GU 2025: Talazoparib and enzalutamide combination improves survival in some patients with prostate cancer
- RAD51 biomarker could complement next-generation sequencing in personalising prostate cancer treatment
- ASCO GU 2025: ENZA-p combination treatment improves survival for metastatic prostate cancer
- Study establishes link between early side effects from prostate cancer radiation and long-term side effects
Cancer Care in Botswana: Medical Oncology
Have you ever wondered what it is like to practice medical oncology in Botswana? In today’s episode, Professor Hans Prenen…
Immune cells that fight cancer become exhausted within hours of first encountering tumours – new research
Mary Philip, Vanderbilt University and Michael Rudloff, Vanderbilt University A key function of our immune system is to detect and…










